股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 上海復旦張江生物醫藥股份有限公司 呈交日期: 2026年2月24日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 01349 說明 H股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 326,000,000 RMB 0.1 RMB 32,600,000 增加 / 減少 (-) RMB 本月底結存 326,000,000 RMB 0.1 RMB 32,600,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688505 | 說明 | | A股（上海證券交易所科創板） | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊 ...

股票近期走势 复旦张江A股与港股近期走势分化。截至2月13日09:32，A股最新价为8.71元，近5日累计上涨1.52%， 但当日微跌0.34%；港股最新价为3.24港元，近5日累计上涨5.54%，当日上涨0.31%。成交方面，2月10 日A股成交额达3881.23万元，当日上涨2.30%，主力资金净流出64.20万元。资金流向显示，2月10日港 股主力资金净流入228.94万港元，但2月11日转为净流出370.70万港元，波动较大。板块层面，港股生物 技术板块近一日上涨0.62%，医疗主题ETF持续走强，对股价形成外部支撑。 经济观察网近7天(2026年2月6日至2月13日)，复旦张江(A股代码：688505，港股代码：01349)热点主要 集中在港股市场的强劲表现、创新药研发进展以及医疗板块整体活跃度提升。根据经济观察网报道，2 月12日公司港股股价上涨，受医疗保健板块上行及注射用FZ-P001钠药物临床试验申请获受理推动。同 时，A股与港股表现分化，港股通医疗ETF走出四连涨，为个股提供板块支撑。 以上内容基于公开资料整理，不构成投资建议。 财报分析 公司2025年业绩预告显示，预计全年归属净利润亏损1 ...

Group 1 - The core viewpoint is that Fudan Zhangjiang's stock performance is diverging between its A-share and Hong Kong share listings, with the Hong Kong stock showing significant gains due to favorable market conditions [1] - As of 09:37, Fudan Zhangjiang's Hong Kong stock (01349.HK) was priced at 3.36 HKD, reflecting a 3.38% increase, outperforming its A-share counterpart [1] - The trading activity in the Hong Kong market is robust, with a turnover rate of 0.10% and a transaction amount of approximately 1.04 million HKD [1] Group 2 - The healthcare sector in the Hong Kong stock market is performing well, with the medical-themed sector continuing to rise, and the Hong Kong Stock Connect medical ETF achieving four consecutive gains [2] - This positive sector performance has created a favorable atmosphere for Fudan Zhangjiang's Hong Kong shares [2] Group 3 - The company has made progress in innovative drug development, with its clinical trial application for FZ-P001 sodium, aimed at visualizing malignant lesions in known or suspected lung cancer patients during surgery, receiving acceptance notification [3] - This development may attract market attention towards the company's potential in the field of precision medicine [3]

Core Viewpoint - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. has announced a change in its continuous supervision sponsor representative due to the work transition of one of the original representatives, ensuring ongoing compliance and oversight of its fundraising activities [1][2]. Group 1 - The company’s initial public offering and listing project on the Sci-Tech Innovation Board has a statutory continuous supervision period from June 19, 2020, to December 31, 2023 [1]. - The original sponsor representatives were Zheng Qianguo and Chen Hengrui, with Zheng Qianguo stepping down due to work changes [2]. - Li Qinhang has been appointed as the new sponsor representative to replace Zheng Qianguo, ensuring the continuity of supervision duties [2]. Group 2 - The company expresses gratitude to Zheng Qianguo for his contributions during the IPO and continuous supervision period [2]. - Li Qinhang holds a bachelor's degree from Nankai University and a master's degree in finance from The Chinese University of Hong Kong, having been involved in investment banking since 2021 [3]. - Li Qinhang has participated in various IPO projects and has a good compliance record in the sponsorship business [3].

Core Viewpoint - Fudan Zhangjiang announced the appointment of new representatives for the ongoing supervision of its initial public offering (IPO) project on the Sci-Tech Innovation Board, following a change in personnel at the sponsoring institution, Guotai Junan Securities [1] Group 1: Project Details - The IPO project is sponsored by Guotai Junan Securities, with a legal supervision period from June 19, 2020, to December 31, 2023 [1] - The company has not yet fully utilized the raised funds, necessitating continued supervision by Guotai Junan [1] Group 2: Personnel Changes - Zheng Qiangguo, one of the original supervising representatives, will no longer serve due to a job change [1] - Li Qinhang has been appointed to replace Zheng Qiangguo as a supervising representative, alongside Chen Hengrui [1]

证券代码：688505 证券简称：复旦张江 编号：临 2026-005 上海复旦张江生物医药股份有限公司 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）首次公开发行股 票并在科创板上市项目（以下简称"本项目"）的保荐机构为国泰海通证券股份 有限公司（以下简称"国泰海通"），本项目法定持续督导期间为 2020 年 6 月 19 日至 2023 年 12 月 31 日，郑乾国先生、陈恒瑞先生为本项目持续督导期间的保 荐代表人。因公司募集资金尚未使用完毕，根据相关规定，国泰海通将继续对公 司募集资金相关事项开展持续督导工作。 公司于近日收到国泰海通出具的《关于更换上海复旦张江生物医药股份有限 公司持续督导保荐代表人的函》。本项目原保荐代表人之一郑乾国先生因工作变 动原因，不再担任本项目的保荐代表人。为保证持续督导工作的有序进行，国泰 海通现委派李沁杭先生（简历附后）接替郑乾国先生担任公司的保荐代表人，继 续履行持续督导职责。本次变更后，本项目 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於更換持續督導保薦代表人的公告》，僅供參閱。該文件及其披露內容乃根據中國法 律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 薛 燕女士（執行董事） 沈 波先生（非執行董事） 余曉陽女士（非執行董事） 王宏廣先生（獨立非執行董事） 林兆榮先生（獨立非執行董事） 徐培龍先生（獨立非執行董事） 曲亞楠女士（職工董事） 中國·上海 二零二六年二月九日 * 僅供識別 上海复旦张江生物医药股份有限公司 关于更换持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容 ...

FF301 截至月份: 2026年1月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01349 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 326,000,000 | RMB | | 0.1 RMB | | 32,600,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 326,000,000 | RMB | | 0.1 RMB | | 32,600,000 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | - ...

Group 1 - Fudan Zhangjiang (01349.HK) experienced a decline of 4% during trading, with a current drop of 3.69%, priced at 3.13 HKD [1] - The trading volume reached 3.7159 million HKD [1]

Group 1 - The core viewpoint of the article indicates that Fudan Zhangjiang (01349) is experiencing a significant decline in stock price, with a drop of 4% during trading and a current price of HKD 3.13, alongside a trading volume of HKD 3.7159 million [1] - The company expects to report an unaudited net loss attributable to shareholders of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to a net profit of RMB 39.73 million in the same period of 2024 [1] - The expected net loss, excluding non-recurring items, is projected to be between RMB 140 million and RMB 200 million, while the net profit for 2024, excluding non-recurring items, was RMB 5.1452 million [1] Group 2 - The company attributes the losses to the advancement of research and development projects, with R&D expenditures rising as a percentage of operating income, amounting to approximately RMB 350 million during the period [1] - Additionally, the retail price of the product "Libao Duo" was reduced starting May 1 of the previous year, leading to a decrease in profit margins, with the product's contribution to the company's profits declining by approximately RMB 100 million year-on-year [1]